ARCHIVES

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

This article is from The Cancer Letter archive.

Vol. 29 No. 9 | September 29, 2006

Download PDF Visit The Full Archive

Related Articles

Blue Cross, Broder Skirmish On Coverage Of Group C Drugs

November 3, 1989

Shubik Named To Another NCA Term In Surprise Move

June 25, 1976

Advanced Screening Provides More Accurate Diagnosis

February 23, 2007

Letrozole Combination Increases PFS In ER+ and HER2-Negative Breast Cancer

January 25, 2013

Shubick Committee Support New System for NCU Review, Action On Chemicals

November 14, 1975

NiH Conference: More Discord Than Consensus At Statement’s Presentation

January 31, 1997